

Publications of the International Breast Cancer Study Group

IBCSG 55-17

442. Malorni L, Tyekucheva S, Gombos A, Hasler-Stub U, Zamgani C, Chakiba-Brugere, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammeler R, Rueep B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L; International Breast Cancer Study Group (a division of ETOP IBCSG Partners Foundation) and the TOUCH Trial (IBCSG 55-17) Investigators. Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17). *Ann Oncol* 2025. doi: 10.1016/j.annonc.2025.10.016. Epub 2025 October 16. (IBCSG 55-17) (Journal Impact Factor 65.4).